Skip to Content
Merck
  • Rare and private spliceosomal gene mutations drive partial, complete, and dual phenocopies of hotspot alterations.

Rare and private spliceosomal gene mutations drive partial, complete, and dual phenocopies of hotspot alterations.

Blood (2020-01-22)
Joseph Pangallo, Jean-Jacques Kiladjian, Bruno Cassinat, Aline Renneville, Justin Taylor, Jacob T Polaski, Khrystyna North, Omar Abdel-Wahab, Robert K Bradley
ABSTRACT

Genes encoding the RNA splicing factors SF3B1, SRSF2, and U2AF1 are subject to frequent missense mutations in clonal hematopoiesis and diverse neoplastic diseases. Most "spliceosomal" mutations affect specific hotspot residues, resulting in splicing changes that promote disease pathophysiology. However, a subset of patients carries spliceosomal mutations that affect non-hotspot residues, whose potential functional contributions to disease are unstudied. Here, we undertook a systematic characterization of diverse rare and private spliceosomal mutations to infer their likely disease relevance. We used isogenic cell lines and primary patient materials to discover that 11 of 14 studied rare and private mutations in SRSF2 and U2AF1 induced distinct splicing alterations, including partially or completely phenocopying the alterations in exon and splice site recognition induced by hotspot mutations or driving "dual" phenocopies that mimicked 2 co-occurring hotspot mutations. Our data suggest that many rare and private spliceosomal mutations contribute to disease pathogenesis and illustrate the utility of molecular assays to inform precision medicine by inferring the potential disease relevance of newly discovered mutations.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-SC-35 Antibody, clone 1SC-4F11, ascites fluid, clone 1SC-4F11, from mouse